# IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

> **NCT07509086** · PHASE2 · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia (PCL)

## Interventions

- **BIOLOGICAL:** IL-15-armored CAR-T cells

## Key facts

- **NCT ID:** NCT07509086
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2028-07-15
- **Final completion:** 2029-07-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509086, "IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07509086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*